Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Payne

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Molecular Autism|July 2, 2026
Autism in neurofibromatosis type 1: prevalence, phenotype and clinical implicationsJonathan M Payne, Kristina M Haebich, Anita K Chisholm, et al.
Annals of Clinical and Translational Neurology|December 5, 2019
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1Jonathan M Payne, Stephen J C Hearps, Karin S Walsh, et al.
JAMA Network Open|June 13, 2024
International Consensus on Standard Outcome Measures for Neurodevelopmental Disorders: A Consensus StatementMelissa Mulraney, Umanga de Silva, Andria Joseph, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Neurology|December 14, 2016
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1Jonathan M Payne, Belinda Barton, Nicole J Ullrich, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Molecular Autism|July 2, 2026
Autism in neurofibromatosis type 1: prevalence, phenotype and clinical implicationsJonathan M Payne, Kristina M Haebich, Anita K Chisholm, et al.
Annals of Clinical and Translational Neurology|December 5, 2019
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1Jonathan M Payne, Stephen J C Hearps, Karin S Walsh, et al.
JAMA Network Open|June 13, 2024
International Consensus on Standard Outcome Measures for Neurodevelopmental Disorders: A Consensus StatementMelissa Mulraney, Umanga de Silva, Andria Joseph, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Neurology|December 14, 2016
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1Jonathan M Payne, Belinda Barton, Nicole J Ullrich, et al.
Pageof 9